Overview

All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2029-11-30

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone compared with that of combination of pomalidomide, bortezomib and dexamethasone in Japanese participants with relapsed/refractory multiple myeloma (RRMM).

Phase:

PHASE3

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

belantamab mafodotin
Bortezomib
Dexamethasone
pomalidomide